Status:
COMPLETED
Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Migraine Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Study to understand the effects of migraine treatments on blood pressure in participants with migraine. The primary hypothesis is that the effect on semi-recumbent mean arterial pressure following the...
Eligibility Criteria
Inclusion
- History of migraine for longer than 6 months.
- Free from migraine 24 hours before each dosing.
- Judged to be in good health.
- Nonsmoker
Exclusion
- Under age of legal consent.
- Legally or mentally incapacitated or has significant emotional problems.
- Taking any medications from about 2 weeks before the first dose of study medication.
- Has had surgery or donated blood or participated in another investigation study within 4 weeks prior to screening
- Currently a regular user of any illicit drugs or has a history of drug/alcohol abuse within about 2 years
- Consumes more than 6 caffeinated beverages per day
Key Trial Info
Start Date :
November 20 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 10 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00701389
Start Date
November 20 2007
End Date
April 10 2008
Last Update
October 17 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.